Hepatitis B vaccination for patients with chronic renal failure

Rj, Schroth; Hitchon, C.; Uhanova, Julia; Zacharias, James; Noreddin, Ayman M.; Taback, SP; Moffatt, MEK

doi:10.1002/14651858.cd003775

Cited by 10 publications

(10 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Members of the latter group, oncology and hemodialysis patients, are at high risk of developing chronic hepatitis B (HBV) infection due to immunosuppression from both the disease process and treatment with chemotherapy, radiotherapy, multiple blood transfusions and hemodialysis. 12 In our study, majority of the patients who developed insufficient antibody to vaccination (64.8%) were the same group of patients. In these patients, effectiveness of the vaccine was tried to be increased with different methods (with different adjuvant or route of administration of vaccine).…”

Section: Discussionsupporting

confidence: 49%

Evaluation of vaccination results in high-risk patients included in hepatitis B vaccination program

Köse¹,

Türken²,

Çavdar³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 49%

Evaluation of vaccination results in high-risk patients included in hepatitis B vaccination program

Köse¹,

Türken²,

Çavdar³

et al. 2010

Human Vaccines

View full text Add to dashboard Cite

“…Early studies demonstrated that renal failure patients benefit from vaccination; however, not all studies have consistently shown this benefit (7). Therefore, we designed this study to compare the response rates of patients at different stages of CKD to HBV vaccination. )…”

Section: Objectivesmentioning

confidence: 99%

Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?

et al. 2011

View full text Add to dashboard Cite

Background: Despite improvement in hepatitis B infection prevention through national vaccination programs, implementation of compulsory and thorough blood donor screening, and reduction of transfusion numbers due to erythropoietin administration, hepatitis B remains a major concern in hemodialysis (HD) centers (1). Compared to a response rate of over 90% in the normal population, only 50 to 60% of those with endstage renal disease (ESRD) achieve protective antibody levels following immunization against hepatitis B (2, 3). Various strategies have been developed to overcome the low seroconversion rate in ESRD patients, including co-administering zinc, gamma-interferon, thymopentin, interleukin-2, and levamisole as immunostimulants or adjuvants (3, 4), changing the injection mode (intradermal versus intramuscular), or doubling the vaccine dose (5). Objectives: Previous studies demonstrated that renal failure patients benefit from HBV vaccination; however, not all studies have demonstrated this. Therefore, we compared the rates of seroconversion (hepatitis B surface antibody [HBsAb] titer > 10 IU/mL) in patients at various stages of chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] < 60 mL/min/1.73 m2) who received HBV vaccination. Patients and Methods: A total of 167 patients in 3 different stages of CKD were vaccinated against HBV. Each patient received the vaccine according to a standardized vaccination schedule consisting of 40 μg of the recombinant vaccine "Engerix" at 0, 1, and 6 months. Eight to 12 weeks after the last dose of vaccination, anti-HBsAb levels were measured. Results: Mean age and eGFR were 57.4 ± 16.5 years and 26.7 ± 14.7 mL/min/1.73 m2, respectively. The overall seroconversion rate was 78%. Although a significant correlation between HBsAb titer and eGFR (r = 0.265, P = 0.001) was observed, in the multivariate analysis using age, CKD stage, diabetes mellitus, and gender as independent variables, the degree of renal function did not significantly contribute to seroconversion. In contrast, higher age (> 60 years) showed a significant negative correlation to seroconversion (odds ratio = 0.22; P = 0.004). Conclousions: CKD patients of advanced age should be vaccinated against HBV. Although higher eGFR was not associated with improved seroconversion, the persistence of seroconversion was not evaluated; future studies should be conducted to develop recommendations for earlier or later vaccination.

show abstract

“…Only 39% of these sought medical care Personnel in facilities where an increased prevalence of HBVinfected persons is likely to be present Breuer et al [28] Cohort study, US Teachers and school children are at increased risk of hepatitis B infection if they come in contact with an HBsAg carrier in the classroom Remis et al [29] Cohort study, Canada Teachers at schools for the mentally handicapped can be at increased risk of hepatitis B infection "vaccin*"; "immunization"; "random*"; "blind*"; "placebo"; "meta-analys*"; "cohort"; "time series"; "case-control"; "ecological"; "cross-sectional"). Additionally, the results of four Cochrane Reviews [32,33,34,35] and one meta-analysis [36] relevant to the topic were considered.…”

Section: Group Of Persons Study Study Setting Resultsmentioning

confidence: 99%

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Harder

Remschmidt

Falkenhorst

et al. 2013

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Hepatitis B vaccination for patients with chronic renal failure

Cited by 10 publications

References 32 publications

Evaluation of vaccination results in high-risk patients included in hepatitis B vaccination program

Evaluation of vaccination results in high-risk patients included in hepatitis B vaccination program

Efficacy of HBV Vaccination in Various Stages of Chronic Kidney Disease: Is Earlier Better?

Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany

Contact Info

Product

Resources

About